Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

GastroEsophageal Cancer Clinical Trial

Official title: Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Status Recruiting

Clinical Trial Summary

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Clinical Trial Description

Primary Objectives:

• Delineate the short-term appetite of patients who undergo minimally-invasive proximal gastrectomy (MIPG) and compare them with those of patients with gastric and gastroesophageal adenocarcinoma who undergo total gastrectomy (MITG). We hypothesize that MIPG is associated with better postoperative appetite levels compared to MITG, which would result in improved nutritional status and maintained body weight after surgery.

Secondary Objectives:

• Assess patient-reported outcomes (PROs) and nutrition measures. We will use the MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI) questionnaire with additional three experimental question items ("PRO questionnaire") to collect preoperative and postoperative patient-reported outcomes (PROs) of QoL and check fasting ghrelin levels to correlate them with reported appetite levels. We will also retrospectively investigate factors associated with improved QoL after surgery, safety of MIPG and MITG, and oncological outcomes after MIPG and MITG. ;

Related Conditions & MeSH terms

• GastroEsophageal Cancer
• Gastrostomy

• NCT number: NCT05205343
• Study type: Observational
• Source: M.D. Anderson Cancer Center
• Contact: Naruhiko Ikoma, MD
• Phone: (832) 729-2675
• Email: nikoma@mdanderson.org
• Status: Recruiting
• Start date: May 11, 2022
• Completion date: May 31, 2024